WASHINGTON, DC , Nov. 01, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today released its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the third quarter and year-to-date 2018.
By further curating information provided by ARM’s data partner Informa, the quarterly data report details industry-specific statistics compiled from 892 cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.
The Q3 2018 data report features commentary from ARM’s Chairman Robert Preti, President & CEO of Hitachi Chemical Advanced Therapeutics Solutions and GM of the Hitachi Chemical Regenerative Medicine Business Sector. The report also spotlights ARM’s 2018 Cell & Gene Meeting on the Mesa, with featured commentary from Peter Marks, Director of the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration, and company executives from Novartis, AveXis, Enzyvant, and Abeona Therapeutics, who participated in two of the panel sessions: “Charting the Path – Lessons from the Pioneers of Cell and Gene Therapy Commercialization” and “Opportunities and Challenges in Rare Disease.”
“Sustained investor interest and a robust clinical pipeline have continued to drive growth in the sector through the third quarter,” said Janet Lambert, ARM’s Chief Executive Officer. “We’re excited to see what the energy and optimism in this sector will bring as we close out the year.”
Highlighted findings from the Q3 2018 data report include:
- Globally, companies active in gene and cell therapies and other regenerative medicines raised more than $2.8 billion in the third quarter of 2018, a 59% increase from Q3 2017; and $10.7 billion in the first three quarters of 2018, a 40% increase year-over-year. The report also includes financial data broken out by technology type and financing type.
- There were 1,003 clinical trials underway worldwide at the close of the third quarter of 2018, with more than 57% of those in oncology and 7% in cardiovascular disorders. The report also includes figures on clinical trials by phase and indication, as well as by technology type.
ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trials by phase, and significant clinical data events.
The report is available online here, with interactive data and downloadable graphics from the report available here. For more information, please visit www.alliancerm.org or contact Lyndsey Scull at lscull@alliancerm.org.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.